Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)

• Company Description    Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $14.47 Daily Weekly Monthly 20 Day Moving Average: 684,346 shares Shares Outstanding: 81.59 (millions) Market Capitalization: $1,180.64 (millions) Beta: 0.39 52 Week High: $27.20 52 Week Low: $9.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.14% -3.54% 12 Week 31.31% 5.56% Year To Date -24.52% -28.37%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 CRESCENT STREET SUITE 103A - WALTHAM,MA 02453 USA ph: 617-272-4600 fax: 760-537-4101 ir@viridiantherapeutics.com http://www.viridiantherapeutics.com

• General Corporate Information    Officers Stephen Mahoney - President; Chief Executive Officer and Director Tomas Kiselak - Chairman Seth Harmon - Chief Financial Officer Sarah Gheuens - Director Peter Harwin - Director Peer Information Viridian Therapeutics, Inc. (CORR.) Viridian Therapeutics, Inc. (RSPI) Viridian Therapeutics, Inc. (CGXP) Viridian Therapeutics, Inc. (BGEN) Viridian Therapeutics, Inc. (GTBP) Viridian Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92790C104 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 81.59 Most Recent Split Date: 11.00 (0.07:1) Beta: 0.39 Market Capitalization: $1,180.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.97 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.84 Price/Cash Flow: - Price / Sales: 3,909.39 EPS Growth vs. Year Ago Period: -10.13% vs. Previous Quarter: -7.41% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% ROE 06/30/25 - - 03/31/25 - -70.61 12/31/24 - -63.01 ROA 06/30/25 - - 03/31/25 - -44.67 12/31/24 - -39.55 Current Ratio 06/30/25 - - 03/31/25 - 19.49 12/31/24 - 15.43 Quick Ratio 06/30/25 - - 03/31/25 - 19.49 12/31/24 - 15.43 Operating Margin 06/30/25 - - 03/31/25 - -102,092.39 12/31/24 - -89,387.09 Net Margin 06/30/25 - - 03/31/25 - -102,092.39 12/31/24 - -89,387.09 Pre-Tax Margin 06/30/25 - - 03/31/25 - -102,092.39 12/31/24 - -89,387.09 Book Value 06/30/25 - - 03/31/25 - 5.09 12/31/24 - 6.09 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.05 12/31/24 - 0.04 Debt-to-Capital 06/30/25 - - 03/31/25 - 3.31 12/31/24 - 2.97

Powered by Zacks Investment Research ©